Market Cap
$195.1B
GILD
GILEAD SCIENCES, INC.
$156.19 ▼ -0.75%
Prev close $157.37Market cap$195.1B
ConsensusStrong Buy
12-mo target$159.85 (+2.3%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)4 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on GILD right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (81%)
Inst. Holders
16 funds
Inst. Value
$697.6M
Inst. Activity
0 buys / 4 sells
Insider Activity
$0.00 buy / $15.9M sell
Insider Net $
-$15.9M
SEC Reports
16
Congressional
4 trades
Price chart 30d +3.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Feb 2, 2027 fda_pdufa
PDUFA: GILD — Yeztugo in HIV pre-exposure prophylaxis — 2027-02-02
FDA target action date 2027-02-02 for GILD (GILEAD SCIENCES, INC.). Drug: Yeztugo. Indication: HIV p
Oct 15, 2026 Insider
Mercier Johanna sold 3,000 shares
Chief Comm & Corp Aff Officer @ $156.22 ($468.7K)
Oct 15, 2026 Insider
Dickinson Andrew D sold 3,000 shares
Chief Financial Officer @ $156.22 ($468.7K)
Oct 14, 2026 Event
Cash v. Gilead Sciences Inc. et al
Court ruling (cand) — Docket: 4:22-cv-08970
Oct 1, 2026 Insider
O'Day Daniel Patrick sold 12,000 shares
Chairman & CEO @ $147.72 ($1.8M)
Sep 30, 2026 Inst.
Assenagon Asset Management S.A. — TRIM
1,560,454 shares ($232.6M)
Sep 30, 2026 Inst.
Vontobel Holding Ltd. — TRIM
702,082 shares ($104.6M)
Aug 27, 2026 Event
Market Event
Original Approval — Type 4 - New Combination
Analyst ratings buy % +3.8%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
81% rate it Buy or better · 37 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 8, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Oct 8, 2026 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Oct 7, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Oct 7, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Oct 7, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Sep 10, 2026 | HSBC | MAINTAIN | Buy | 55% |
| Aug 5, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Aug 5, 2026 | Cantor Fitzgerald | REITERATE | Overweight | 49% |
| Aug 5, 2026 | Needham | REITERATE | Buy | 50% |
| Jul 29, 2026 | Barclays | MAINTAIN | Equal-Weight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 21 | 7 | 0 | 0 | 81% | |
| Aug 1, 2026 | 9 | 21 | 7 | 0 | 0 | 81% | |
| Jul 1, 2026 | 10 | 20 | 7 | 0 | 0 | 81% | |
| Jun 1, 2026 | 11 | 21 | 7 | 0 | 0 | 82% | |
| May 1, 2026 | 11 | 20 | 8 | 0 | 0 | 79% | |
| Apr 1, 2026 | 11 | 20 | 8 | 0 | 0 | 79% | |
| Mar 1, 2026 | 10 | 20 | 8 | 0 | 0 | 79% | |
| Feb 1, 2026 | 10 | 20 | 7 | 0 | 0 | 81% |
Price targets
Where 26 covering analysts think GILD trades over the next 12 months.
$159.85 +2.3% upside Hold
Current$156.19 Low$126.00 Median$165.00 High$180.00 26 analysts
$126.00$180.00
Analyst rating Buy· 1.7/5 as of Oct 19, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 4 bullish, 2 bearish, 0 mixed, 10 neutral · avg impact 3.4/10.
BULLISHANALYST-UPGRADE2/10
Maxim Group upgrades GILD to Buy — PT $165 (+26.4%)
May 20, 2026
BEARISHANALYST-DOWNGRADE4/10
Leerink Partners downgrades GILD to Market Perform — PT $127 (-4.7%)
Jul 21, 2026
BULLISHANALYST-UPGRADE3/10
HSBC upgrades GILD to Buy — PT $155 (+18%)
Jul 6, 2026
NEUTRALCLUSTER2/10
GILD insiders, including Chairman & CEO Daniel O'Day and Director Anthony Welters, sold a total of ~
Sep 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Feb 2, 2027
fda_pdufa
PDUFA: GILD — Yeztugo in HIV pre-exposure prophylaxis — 2027-02-02
FDA target action date 2027-02-02 for GILD (GILEAD SCIENCES, INC.). Drug: Yeztugo. Indication: HIV pre-exposure prophylaxis. PDUFA target action date
Dec 23, 2026
fda_pdufa
PDUFA: GILD — anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma (4L+) — 2026-12-23
FDA target action date 2026-12-23 for GILD (GILEAD SCIENCES, INC.). Drug: anitocabtagene autoleucel (anito-cel). Indication: relapsed or refractory mu
Oct 22, 2026
earnings_calendar
GILD Q3 2026 Earnings Scheduled — 2026-10-22
Oct 19, 2026
Clinical Trial
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Oct 19, 2026
clinical_trial_readout
T-90d Trial Readout: Tilpisertib Fosmecarbil (Phase 2)
Trial: Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis Sponsor: Gilead Sciences Phase: Phase 2
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.20 | $1.99–$2.68 | -10.9% | +2.4% | 5↑ 2↓ | $7.8B | 22 |
| Next Q | $2.17 | $1.92–$3.13 | 16.5% | -1.0% | 3↑ 4↓ | $8.1B | 19 |
| Current FY | $-0.40 | $-0.62–$-0.02 | -104.9% | +6.2% | 6↑ 1↓ | $30.7B | 27 |
| Next FY | $9.94 | $9.19–$11.44 | 2586.6% | +0.5% | 5↑ 2↓ | $32.8B | 25 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.200 | — |
| 7d ago | $2.177 | +0.022 |
| 30d ago | $2.148 | +0.052 |
| 60d ago | $2.152 | +0.048 |
| 90d ago | $2.227 | -0.028 |
Institutional ownership
Which big funds own GILD (from quarterly 13F filings) and who is adding or trimming.
16 institutional holders with $697.6M total value (4,780,411 shares) as of 2026-Q3. Top holders: Assenagon, Vontobel, FJARDE. Net selling activity: 4 institutions trimmed/exited vs 0 added.
Top holders — 2026-Q3
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Assenagon Asset Management S.A. | 1,560,454 | $232.6M | 33.3% | TRIM -31.8% |
| Vontobel Holding Ltd. | 702,082 | $104.6M | 15.0% | TRIM -25.9% |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | 558,657 | $83.3M | 11.9% | ADD +43.4% |
| Czech National Bank | 356,269 | $53.1M | 7.6% | — |
| ATWOOD & PALMER INC | 351,309 | $52.4M | 7.5% | — |
| IFM Investors Pty Ltd | 300,000 | $44.7M | 6.4% | — |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 358,001 | $38.7M | 5.5% | TRIM -40.7% |
| BANQUE PICTET & CIE SA | 197,882 | $29.5M | 4.2% | — |
| TD Waterhouse Canada Inc. | 153,802 | $22.7M | 3.3% | TRIM -68.1% |
| Concurrent Investment Advisors, LLC | 87,099 | $13.0M | 1.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Assenagon Asset Management S.A. | TRIM | 2,287,888 | 1,560,454 | -31.8% | $232.6M |
| Vontobel Holding Ltd. | TRIM | 947,749 | 702,082 | -25.9% | $104.6M |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 603,836 | 358,001 | -40.7% | $38.7M |
| TD Waterhouse Canada Inc. | TRIM | 482,201 | 153,802 | -68.1% | $22.7M |
| NORGES BANK | NEW | — | 21,965,555 | — | $2.8B |
| JPMORGAN CHASE & CO | TRIM | 33,992,410 | 20,820,621 | -38.7% | $2.6B |
| Capital Research Global Investors | TRIM | 27,127,533 | 19,393,296 | -28.5% | $2.5B |
| PeakShares LLC | NEW | — | 7,920 | — | $1.0B |
| Boston Partners | ADD | 4,255,122 | 6,017,958 | +41.4% | $761.6M |
| Qube Research & Technologies Ltd | DOUBLED | 121,052 | 3,086,166 | +2449.5% | $389.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net -$15.9M — $0.00 bought, $15.9M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 3,000 | $156.22 | $468.7K |
| Oct 15, 2026 | Dickinson Andrew D | Chief Financial Officer | SELL | 3,000 | $156.22 | $468.7K |
| Oct 1, 2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | 12,000 | $147.72 | $1.8M |
| Oct 1, 2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | 3,000 | $148.63 | $445.9K |
| Sep 22, 2026 | Burkhart Erin | SVP, Controllership | TAX W/H | 768 | $152.67 | $117.3K |
| Sep 22, 2026 | Burkhart Erin | SVP, Controllership | EXERCISE | 2,223 | — | — |
| Sep 15, 2026 | Dickinson Andrew D | Chief Financial Officer | SELL | 3,000 | $145.29 | $435.9K |
| Sep 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 600 | $145.29 | $87.2K |
| Sep 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 800 | $144.46 | $115.6K |
| Sep 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | 1,600 | $143.69 | $229.9K |
Congressional trades
GILD trades disclosed by members of Congress, with disclosure delay.
3 members · 3 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Ro Khanna | D | HOUSE | SELL | $1,001 - $15,000 | Gilead Sciences Inc | Sep 7, 2026(29d) |
| May 6, 2026 | Jared Moskowitz | D | HOUSE | BUY | $1,001 - $15,000 | Gilead Sciences Inc | Jun 22, 2026(48d) |
| May 6, 2026 | Jared Moskowitz | D | HOUSE | BUY | $1,001 - $15,000 | Gilead Sciences Inc | Jun 22, 2026(48d) |
| Jan 27, 2026 | Joshua Gottheimer | D | HOUSE | BUY | $1,001 - $15,000 | Gilead Sciences Inc | Feb 27, 2026(32d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GILD.
Shares short
21,828,725
Settlement Sep 30, 2026
Change vs prior
+19.3%
Semi-monthly cycle
Days to cover
3.4
At avg daily volume
Of shares outstanding
≈1.8%
Estimate — not % of float
All GILD filing & press-release reports (16)
- Maxim Group upgrades GILD to Buy — PT $165 (+26.4%)May 20, 2026
- Leerink Partners downgrades GILD to Market Perform — PT $127 (-4.7%)Jul 21, 2026
- HSBC upgrades GILD to Buy — PT $155 (+18%)Jul 6, 2026
- CLUSTER reportSep 3, 2026
- CLUSTER reportAug 27, 2026
- CLUSTER reportAug 21, 2026
- COURT-RULING reportAug 19, 2026
- CLUSTER reportAug 18, 2026
- COURT-RULING reportAug 14, 2026
- S-3ASR reportAug 6, 2026
- CLUSTER reportJul 16, 2026
- CLUSTER reportJun 16, 2026
- 424B5 reportMay 18, 2026
- 424B5 reportMay 14, 2026
- CLUSTER reportApr 16, 2026
- DEFA14A reportMar 20, 2026